Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.43 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)1.32M
Market Cap
$7.56B
Enterprise Value$6.10B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Feb 26, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.59
Shares Outstanding182,349,820
10 Day Avg. Volume1,100,642
30 Day Avg. Volume1,315,073
Standard Deviation0.17
R-Squared0.20
Alpha-0.00099
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9598.93
Price to Cash Flow (P/CF)-13.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit527.08
Enterprise Value/Ebitda-9.71
Forecast
1Y Price Target
$74.36Price Target Upside75.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe updated RMC-6236 monotherapy data in non-small cell lung cancer is promising and supports the upcoming Phase III RASolve 301 study.
Strategic ExpansionRevolution Medicines plans to advance RMC-6236 into earlier lines of therapy for metastatic PDAC patients, indicating expansion potential.
Bears Say
Stock PerformanceShare weakness may have been driven by new concerns on ‘6236 tolerability following dose reduction in NSCLC.
---
Ownership Overview
6.45% Insiders
25.68% Mutual Funds
0.05% Other Institutional Investors
52.85% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $28.43 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $7.56B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.047.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -0.99.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 182,349,820 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -0.539%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
---
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.36 (75.96% Upside)
$74.36 (75.96% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 66%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.87%
12-Months-Change
Fundamentals
Return on Equity
-47.18%
Trailing 12-Months
Asset Growth
79.12%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
---
RVMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong progress in clinical trials for RMC-6236 and RMC-9805, a robust financial position, and future plans for pipeline expansion. However, increased expenses and a delay in the lung cancer trial posed challenges.Read More>---
RVMD Stock 12 Month Forecast
Average Price Target
$74.36
▲(75.96% Upside)
Technical Analysis
Best Analysts Covering RVMD
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+31.89%
reiterated a buy rating 3 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +31.89% per trade.
---